PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Clindamycin - Bacterial infection

PAD Profile : Clindamycin - Bacterial infection

Keywords :
antibiotic, antibacterial
Brand Names Include :
Dalacin C

Traffic Light Status

Status 1 of 2.

Status :
Blue
Important
Formulations :
  • Capsules
  • Liquid
Important Information :
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Use in primary care when indicated by microbiology eg on culture results. Clindamycin has a high association with the development of Clostridium Difficile.  Patients and carers should be advised to stop clindamycin if diarrhoea develops. 
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Red
Important
Formulations :
  • Injection
Important Information :
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation. Clindamycin has a high association with the development of Clostridium Difficile.  Patients and carers should be advised to stop clindamycin if diarrhoea develops.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

No committee recommendations returned.

Associated BNF Codes

05. Infections
05.01.06. Clindamycin and lincomycin
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More